{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T19:49:53Z","timestamp":1782157793206,"version":"3.54.5"},"reference-count":181,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["3 Biotech"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13205-026-04846-4","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:50:21Z","timestamp":1779270621000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nanoparticle-based strategies as emerging tools for oral chemotherapy of colorectal cancer"],"prefix":"10.1007","volume":"16","author":[{"given":"Hiranmoy","family":"Bhattacharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhajit","family":"Kandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2148-2331","authenticated-orcid":false,"given":"Asis","family":"Bala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saikat","family":"Dewanjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"3","key":"4846_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020, GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"4846_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1055\/s-0029-1242458","volume":"22","author":"FA Haggar","year":"2009","unstructured":"Haggar FA, Boushey RP (2009) Colorectal cancer epidemiology, incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 22(4):191\u2013197. https:\/\/doi.org\/10.1055\/s-0029-1242458","journal-title":"Clin Colon Rectal Surg"},{"issue":"3","key":"4846_CR3","first-page":"105","volume":"7","author":"AR Marley","year":"2016","unstructured":"Marley AR, Nan H (2016) Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet 7(3):105\u2013114","journal-title":"Int J Mol Epidemiol Genet"},{"issue":"10207","key":"4846_CR4","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB (2019) Colorectal cancer. Lancet 394(10207):1467\u20131480. https:\/\/doi.org\/10.1016\/S0140-6736(19)32319-0","journal-title":"Lancet"},{"key":"4846_CR5","doi-asserted-by":"publisher","first-page":"901559","DOI":"10.3389\/fphar.2022.901559","volume":"13","author":"G Tong","year":"2022","unstructured":"Tong G, Peng T, Chen Y, Sha L, Dai H, Xiang Y et al (2022) Effects of GLP-1 receptor agonists on the biological behavior of colorectal cancer cells by regulating PI3K\/AKT\/mTOR signaling pathway. Front Pharmacol 13:901559. https:\/\/doi.org\/10.3389\/fphar.2022.901559","journal-title":"Front Pharmacol"},{"issue":"3","key":"4846_CR6","doi-asserted-by":"publisher","first-page":"e569","DOI":"10.1016\/j.clcc.2018.05.008","volume":"17","author":"MM Lee","year":"2018","unstructured":"Lee MM, MacKinlay A, Semira C, Schieber C, Jimeno Yepes AJ, Lee B et al (2018) Stage-based Variation in the Effect of Primary Tumor Side on All Stages of Colorectal Cancer Recurrence and Survival. Clin Colorectal Cancer 17(3):e569\u2013e577. https:\/\/doi.org\/10.1016\/j.clcc.2018.05.008","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"4846_CR7","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3390\/pharmaceutics14061213","volume":"14","author":"N Krasteva","year":"2022","unstructured":"Krasteva N, Georgieva M (2022) Promising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials. Pharmaceutics 14(6):1213. https:\/\/doi.org\/10.3390\/pharmaceutics14061213","journal-title":"Pharmaceutics"},{"issue":"3","key":"4846_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000446486","volume":"32","author":"MF H\u00e4fner","year":"2016","unstructured":"H\u00e4fner MF, Debus J (2016) Radiotherapy for colorectal cancer, current standards and future perspectives. Visc Med 32(3):172\u2013177. https:\/\/doi.org\/10.1159\/000446486","journal-title":"Visc Med"},{"issue":"4","key":"4846_CR9","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.ijrobp.2009.03.010","volume":"76","author":"K Bruheim","year":"2010","unstructured":"Bruheim K, Guren MG, Skovlund E, Hjermstad MJ, Dahl O, Frykholm G et al (2010) Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 76(4):1005\u20131011. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.03.010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"4846_CR10","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.3390\/pharmaceutics15112620","volume":"15","author":"AS Adebayo","year":"2023","unstructured":"Adebayo AS, Agbaje K, Adesina SK, Olajubutu O (2023) Colorectal cancer, disease process, current treatment options, and future perspectives. Pharmaceutics 15(11):2620. https:\/\/doi.org\/10.3390\/pharmaceutics15112620","journal-title":"Pharmaceutics"},{"key":"4846_CR11","doi-asserted-by":"publisher","first-page":"110993","DOI":"10.1016\/j.radonc.2025.110993","volume":"209","author":"J Li","year":"2025","unstructured":"Li J, He HG, Guan C, Ding Y, Hu X (2025) Dynamic joint prediction model of severe radiation-induced oral mucositis among nasopharyngeal carcinoma, a prospective longitudinal study. Radiother Oncol 209:110993. https:\/\/doi.org\/10.1016\/j.radonc.2025.110993","journal-title":"Radiother Oncol"},{"issue":"4","key":"4846_CR12","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/ags3.12576","volume":"6","author":"H Yamamoto","year":"2022","unstructured":"Yamamoto H (2022) Micrometastasis in lymph nodes of colorectal cancer. Ann Gastroenterol Surg 6(4):466\u2013473. https:\/\/doi.org\/10.1002\/ags3.12576","journal-title":"Ann Gastroenterol Surg"},{"issue":"9","key":"4846_CR13","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.3390\/pharmaceutics15092233","volume":"15","author":"J Li","year":"2023","unstructured":"Li J, Wang Q, Xia G, Adilijiang N, Li Y, Hou Z et al (2023) Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy. Pharmaceutics 15(9):2233. https:\/\/doi.org\/10.3390\/pharmaceutics15092233","journal-title":"Pharmaceutics"},{"issue":"7","key":"4846_CR14","doi-asserted-by":"publisher","first-page":"CD008398","DOI":"10.1002\/14651858.CD008398.pub2","volume":"7","author":"F Chionh","year":"2017","unstructured":"Chionh F, Lau D, Yeung Y, Price T, Tebbutt N (2017) Oral versus intravenous fluoropyrimidines for colorectal cancer. Cochrane Database Syst Rev 7(7):CD008398. https:\/\/doi.org\/10.1002\/14651858.CD008398.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"4846_CR15","doi-asserted-by":"publisher","first-page":"670124","DOI":"10.3389\/fbioe.2021.670124","volume":"9","author":"K Ying","year":"2021","unstructured":"Ying K, Bai B, Gao X, Xu Y, Wang H, Xie B (2021) Orally Administrable Therapeutic Nanoparticles for the Treatment of Colorectal Cancer. Front Bioeng Biotechnol 9:670124. https:\/\/doi.org\/10.3389\/fbioe.2021.670124","journal-title":"Front Bioeng Biotechnol"},{"key":"4846_CR16","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jconrel.2022.12.029","volume":"353","author":"LE McCoubrey","year":"2023","unstructured":"McCoubrey LE, Favaron A, Awad A, Orlu M, Gaisford S, Basit AW (2023) Colonic drug delivery, Formulating the next generation of colon-targeted therapeutics. J Control Release 353:1107\u20131126. https:\/\/doi.org\/10.1016\/j.jconrel.2022.12.029","journal-title":"J Control Release"},{"key":"4846_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/bs.acr.2022.02.007","volume":"155","author":"HI Akbarali","year":"2022","unstructured":"Akbarali HI, Muchhala KH, Jessup DK, Cheatham S (2022) Chemotherapy induced gastrointestinal toxicities. Adv Cancer Res 155:131\u2013166. https:\/\/doi.org\/10.1016\/bs.acr.2022.02.007","journal-title":"Adv Cancer Res"},{"issue":"18","key":"4846_CR18","doi-asserted-by":"publisher","first-page":"115556","DOI":"10.1016\/j.bmc.2020.115556","volume":"28","author":"Z Ka\u017amierczak","year":"2020","unstructured":"Ka\u017amierczak Z, Szostak-Paluch K, Przyby\u0142o M, Langner M, Witkiewicz W, J\u0119druchniewicz N et al (2020) Endocytosis in cellular uptake of drug delivery vectors, Molecular aspects in drug development. Bioorg Med Chem 28(18):115556. https:\/\/doi.org\/10.1016\/j.bmc.2020.115556","journal-title":"Bioorg Med Chem"},{"issue":"4561","key":"4846_CR19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/179663a0","volume":"179","author":"C Heidelberger","year":"1957","unstructured":"Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R et al (1957) Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179(4561):663\u2013666. https:\/\/doi.org\/10.1038\/179663a0","journal-title":"Nature"},{"issue":"10","key":"4846_CR20","doi-asserted-by":"publisher","first-page":"101778","DOI":"10.1016\/j.xcrm.2024.101778","volume":"5","author":"JK Chen","year":"2024","unstructured":"Chen JK, Merrick KA, Kong YW, Izrael-Tomasevic A, Eng G, Handly ED et al (2024) An RNA damage response network mediates the lethality of 5-FU in colorectal cancer. Cell Rep Med 5(10):101778. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101778","journal-title":"Cell Rep Med"},{"issue":"34","key":"4846_CR21","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.3748\/wjg.v24.i34.3834","volume":"24","author":"K Van der Jeught","year":"2018","unstructured":"Van der Jeught K, Xu HC, Li YJ, Lu XB, Ji G (2018) Drug resistance and new therapies in colorectal cancer. World J Gastroenterol 24(34):3834\u20133848. https:\/\/doi.org\/10.3748\/wjg.v24.i34.3834","journal-title":"World J Gastroenterol"},{"key":"4846_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/ott.s3465","volume":"2","author":"G Tonini","year":"2009","unstructured":"Tonini G, Calvieri A, Vincenzi B, Santini D (2009) First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab. Onco Targets Ther 2:73\u201382. https:\/\/doi.org\/10.2147\/ott.s3465","journal-title":"Onco Targets Ther"},{"issue":"3","key":"4846_CR23","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.3390\/cancers2031717","volume":"2","author":"K Miura","year":"2010","unstructured":"Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, Ogawa H et al (2010) 5-fu metabolism in cancer and orally-administrable 5-FU drugs. Cancers (Basel) 2(3):1717\u20131730. https:\/\/doi.org\/10.3390\/cancers2031717","journal-title":"Cancers (Basel)"},{"key":"4846_CR24","doi-asserted-by":"publisher","first-page":"111285","DOI":"10.1016\/j.biopha.2021.111285","volume":"137","author":"C Sethy","year":"2021","unstructured":"Sethy C, Kundu CN (2021) 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomed Pharmacother 137:111285. https:\/\/doi.org\/10.1016\/j.biopha.2021.111285","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"4846_CR25","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1158\/1535-7163.MCT-14-0748","volume":"14","author":"S Kiyonari","year":"2015","unstructured":"Kiyonari S, Iimori M, Matsuoka K, Watanabe S, Morikawa-Ichinose T, Miura D et al (2015) The 1,2-Diaminocyclohexane Carrier Ligand in Oxaliplatin Induces p53-Dependent Transcriptional Repression of Factors Involved in Thymidylate Biosynthesis. Mol Cancer Ther 14(10):2332\u20132342. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0748","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"4846_CR26","first-page":"2350","volume":"7","author":"F Li","year":"2017","unstructured":"Li F, Jiang T, Li Q, Ling X (2017) Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action, did we miss something in CPT analogue molecular targets for treating human disease such as cancer? Am J Cancer Res 7(12):2350\u20132394","journal-title":"Am J Cancer Res"},{"issue":"23","key":"4846_CR27","doi-asserted-by":"publisher","first-page":"19469","DOI":"10.18632\/oncotarget.3625","volume":"6","author":"Z Fu","year":"2015","unstructured":"Fu Z, Chen X, Guan S, Yan Y, Lin H, Hua ZC (2015) Curcumin inhibits angiogenesis and improves defective hematopoiesis induced by tumor-derived VEGF in tumor model through modulating VEGF-VEGFR2 signaling pathway. Oncotarget 6(23):19469\u201319482. https:\/\/doi.org\/10.18632\/oncotarget.3625","journal-title":"Oncotarget"},{"issue":"39","key":"4846_CR28","doi-asserted-by":"publisher","first-page":"7724","DOI":"10.1039\/c5tb01245g","volume":"3","author":"B Xiao","year":"2015","unstructured":"Xiao B, Si X, Han MK, Viennois E, Zhang M, Merlin D (2015) Co-delivery of camptothecin and curcumin by cationic polymeric nanoparticles for synergistic colon cancer combination chemotherapy. J Mater Chem B 3(39):7724\u20137733. https:\/\/doi.org\/10.1039\/c5tb01245g","journal-title":"J Mater Chem B"},{"issue":"1","key":"4846_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12951-022-01586-4","volume":"20","author":"Y Guo","year":"2022","unstructured":"Guo Y, Wang M, Zou Y, Jin L, Zhao Z, Liu Q et al (2022) Mechanisms of chemotherapeutic resistance and the application of targeted nanoparticles for enhanced chemotherapy in colorectal cancer. J Nanobiotechnol 20(1):371. https:\/\/doi.org\/10.1186\/s12951-022-01586-4","journal-title":"J Nanobiotechnol"},{"key":"4846_CR30","doi-asserted-by":"publisher","first-page":"175883592110090","DOI":"10.1177\/17588359211009001","volume":"13","author":"P Garc\u00eda-Alfonso","year":"2021","unstructured":"Garc\u00eda-Alfonso P, Mu\u00f1oz Mart\u00edn AJ, Ortega Mor\u00e1n L, Soto Alsar J, Torres P\u00e9rez-Solero G, Blanco Codesido M et al (2021) Oral drugs in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol 13:17588359211009001. https:\/\/doi.org\/10.1177\/17588359211009001","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"4846_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/s0959-8049(01)00371-9","volume":"38","author":"MM Borner","year":"2002","unstructured":"Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A et al (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38(3):349\u2013358. https:\/\/doi.org\/10.1016\/s0959-8049(01)00371-9","journal-title":"Eur J Cancer"},{"issue":"4","key":"4846_CR32","first-page":"331","volume":"67","author":"T Delaunoit","year":"2004","unstructured":"Delaunoit T, Neczyporenko F, Hendlisz A, Eisendrath P, Bleiberg H (2004) Oral fluoropyrimidines in colorectal cancer, a door open to the future? Acta Gastroenterol Belg 67(4):331\u2013333","journal-title":"Acta Gastroenterol Belg"},{"issue":"2","key":"4846_CR33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1365-2354.2005.00531.x","volume":"14","author":"AP Lima","year":"2005","unstructured":"Lima AP, del Giglio A (2005) Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience. Eur J Cancer Care (Engl) 14(2):151\u2013154. https:\/\/doi.org\/10.1111\/j.1365-2354.2005.00531.x","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"6","key":"4846_CR34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/17425247.2020.1748005","volume":"17","author":"X Zhang","year":"2020","unstructured":"Zhang X, Song H, Canup BSB, Xiao B (2020) Orally delivered targeted nanotherapeutics for the treatment of colorectal cancer. Expert Opin Drug Deliv 17(6):781\u2013790. https:\/\/doi.org\/10.1080\/17425247.2020.1748005","journal-title":"Expert Opin Drug Deliv"},{"issue":"5","key":"4846_CR35","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.nano.2015.02.018","volume":"11","author":"S Hua","year":"2015","unstructured":"Hua S, Marks E, Schneider JJ, Keely S (2015) Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease, selective targeting to diseased versus healthy tissue. Nanomedicine 11(5):1117\u20131132. https:\/\/doi.org\/10.1016\/j.nano.2015.02.018","journal-title":"Nanomedicine"},{"issue":"7","key":"4846_CR36","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3390\/nano14070557","volume":"14","author":"N Wang","year":"2024","unstructured":"Wang N, Chen L, Huang W, Gao Z, Jin M (2024) Current Advances of Nanomaterial-Based Oral Drug Delivery for Colorectal Cancer Treatment. Nanomaterials (Basel) 14(7):557. https:\/\/doi.org\/10.3390\/nano14070557","journal-title":"Nanomaterials (Basel)"},{"issue":"1","key":"4846_CR37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/gutjnl-2022-328166","volume":"72","author":"N Proch\u00e1zkov\u00e1","year":"2023","unstructured":"Proch\u00e1zkov\u00e1 N, Falony G, Dragsted LO, Licht TR, Raes J, Roager HM (2023) Advancing human gut microbiota research by considering gut transit time. Gut 72(1):180\u2013191. https:\/\/doi.org\/10.1136\/gutjnl-2022-328166","journal-title":"Gut"},{"issue":"2","key":"4846_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/nmo.12713","volume":"28","author":"AM Haase","year":"2016","unstructured":"Haase AM, Gregersen T, Christensen LA, Agnholt J, Dahlerup JF, Schlageter V et al (2016) Regional gastrointestinal transit times in severe ulcerative colitis. Neurogastroenterol Motil 28(2):217\u2013224. https:\/\/doi.org\/10.1111\/nmo.12713","journal-title":"Neurogastroenterol Motil"},{"issue":"4","key":"4846_CR39","doi-asserted-by":"publisher","first-page":"G405","DOI":"10.1152\/ajpgi.00316.2021","volume":"322","author":"SJ Keely","year":"2022","unstructured":"Keely SJ, Barrett KE (2022) Intestinal secretory mechanisms and diarrhea. Am J Physiol Gastrointest Liver Physiol 322(4):G405\u2013G420. https:\/\/doi.org\/10.1152\/ajpgi.00316.2021","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"4846_CR40","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.addr.2018.06.021","volume":"146","author":"NG Kotla","year":"2019","unstructured":"Kotla NG, Rana S, Sivaraman G, Sunnapu O, Vemula PK, Pandit A, Rochev Y (2019) Bioresponsive drug delivery systems in intestinal inflammation, State-of-the-art and future perspectives. Adv Drug Deliv Rev 146:248\u2013266. https:\/\/doi.org\/10.1016\/j.addr.2018.06.021","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"4846_CR41","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1021\/acs.molpharmaceut.7b00095","volume":"14","author":"K Murray","year":"2017","unstructured":"Murray K, Hoad CL, Mudie DM, Wright J, Heissam K, Abrehart N et al (2017) Magnetic Resonance Imaging Quantification of Fasted State Colonic Liquid Pockets in Healthy Humans. Mol Pharm 14(8):2629\u20132638. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00095","journal-title":"Mol Pharm"},{"issue":"3","key":"4846_CR42","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/nu13030893","volume":"13","author":"DM Livovsky","year":"2021","unstructured":"Livovsky DM, Azpiroz F (2021) Gastrointestinal Contributions to the Postprandial Experience. Nutrients 13(3):893. https:\/\/doi.org\/10.3390\/nu13030893","journal-title":"Nutrients"},{"key":"4846_CR43","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fphar.2020.00524","volume":"11","author":"S Hua","year":"2020","unstructured":"Hua S (2020) Advances in Oral Drug Delivery for Regional Targeting in the Gastrointestinal Tract - Influence of Physiological, Pathophysiological and Pharmaceutical Factors. Front Pharmacol 11:524. https:\/\/doi.org\/10.3389\/fphar.2020.00524","journal-title":"Front Pharmacol"},{"issue":"24","key":"4846_CR44","doi-asserted-by":"publisher","first-page":"518","DOI":"10.21037\/atm.2016.11.82","volume":"4","author":"DW Clark","year":"2016","unstructured":"Clark DW, Palle K (2016) Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets. Ann Transl Med 4(24):518. https:\/\/doi.org\/10.21037\/atm.2016.11.82","journal-title":"Ann Transl Med"},{"issue":"10","key":"4846_CR45","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41589-022-01048-w","volume":"18","author":"Z Feng","year":"2022","unstructured":"Feng Z, Hom ME, Bearrood TE, Rosenthal ZC, Fern\u00e1ndez D, Ondrus AE et al (2022) Targeting colorectal cancer with small-molecule inhibitors of ALDH1B1. Nat Chem Biol 18(10):1065\u20131075. https:\/\/doi.org\/10.1038\/s41589-022-01048-w","journal-title":"Nat Chem Biol"},{"issue":"11","key":"4846_CR46","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.3390\/cancers11111776","volume":"11","author":"YJ Na","year":"2019","unstructured":"Na YJ, Kim BR, Kim JL, Kang S, Jeong YA, Park SH et al (2019) Deficiency of 15-LOX-1 Induces Radioresistance through Downregulation of MacroH2A2 in Colorectal Cancer. Cancers (Basel) 11(11):1776. https:\/\/doi.org\/10.3390\/cancers11111776","journal-title":"Cancers (Basel)"},{"key":"4846_CR47","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3389\/fonc.2019.00927","volume":"9","author":"M Murdocca","year":"2019","unstructured":"Murdocca M, Capuano R, Pucci S, Cicconi R, Polidoro C, Catini A et al (2019) Targeting LOX-1 Inhibits Colorectal Cancer Metastasis in an Animal Model. Front Oncol 9:927. https:\/\/doi.org\/10.3389\/fonc.2019.00927","journal-title":"Front Oncol"},{"issue":"1","key":"4846_CR48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000511244","volume":"8","author":"A Farhat","year":"2021","unstructured":"Farhat A, Ferns GA, Ashrafi K, Arjmand MH (2021) Lysyl Oxidase Mechanisms to Mediate Gastrointestinal Cancer Progression. Gastrointest Tumors 8(1):33\u201340. https:\/\/doi.org\/10.1159\/000511244","journal-title":"Gastrointest Tumors"},{"issue":"10\u201311","key":"4846_CR49","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41417-020-00279-0","volume":"28","author":"M Murdocca","year":"2021","unstructured":"Murdocca M, De Masi C, Pucci S, Mango R, Novelli G, Di Natale C et al (2021) LOX-1 and cancer, an indissoluble liaison. Cancer Gene Ther 28(10\u201311):1088\u20131098. https:\/\/doi.org\/10.1038\/s41417-020-00279-0","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"4846_CR50","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3390\/pharmaceutics13020161","volume":"13","author":"G Lemmens","year":"2021","unstructured":"Lemmens G, Van Camp A, Kourula S, Vanuytsel T, Augustijns P (2021) Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring. Pharmaceutics 13(2):161. https:\/\/doi.org\/10.3390\/pharmaceutics13020161","journal-title":"Pharmaceutics"},{"issue":"3","key":"4846_CR51","doi-asserted-by":"publisher","first-page":"151486","DOI":"10.1016\/j.ijmm.2021.151486","volume":"311","author":"A Iftekhar","year":"2021","unstructured":"Iftekhar A, Sigal M (2021) Defence and adaptation mechanisms of the intestinal epithelium upon infection. Int J Med Microbiol 311(3):151486. https:\/\/doi.org\/10.1016\/j.ijmm.2021.151486","journal-title":"Int J Med Microbiol"},{"issue":"2","key":"4846_CR52","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/mi.2012.81","volume":"6","author":"M Kesimer","year":"2013","unstructured":"Kesimer M, Ehre C, Burns KA, Davis CW, Sheehan JK, Pickles RJ (2013) Molecular organization of the mucins and glycocalyx underlying mucus transport over mucosal surfaces of the airways. Mucosal Immunol 6(2):379\u2013392. https:\/\/doi.org\/10.1038\/mi.2012.81","journal-title":"Mucosal Immunol"},{"issue":"11","key":"4846_CR53","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1080\/17425247.2023.2289586","volume":"20","author":"F Laffleur","year":"2023","unstructured":"Laffleur F, Mayer AH (2023) Oral nanoparticulate drug delivery systems for the treatment of intestinal bowel disease and colorectal cancer. Expert Opin Drug Deliv 20(11):1595\u20131607. https:\/\/doi.org\/10.1080\/17425247.2023.2289586","journal-title":"Expert Opin Drug Deliv"},{"key":"4846_CR54","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.addr.2017.11.001","volume":"124","author":"JY Lock","year":"2018","unstructured":"Lock JY, Carlson TL, Carrier RL (2018) Mucus models to evaluate the diffusion of drugs and particles. Adv Drug Deliv Rev 124:34\u201349. https:\/\/doi.org\/10.1016\/j.addr.2017.11.001","journal-title":"Adv Drug Deliv Rev"},{"issue":"32","key":"4846_CR55","doi-asserted-by":"publisher","first-page":"4475","DOI":"10.3748\/wjg.v28.i32.4475","volume":"28","author":"A Loktionov","year":"2022","unstructured":"Loktionov A (2022) Colon mucus in colorectal neoplasia and beyond. World J Gastroenterol 28(32):4475\u20134492. https:\/\/doi.org\/10.3748\/wjg.v28.i32.4475","journal-title":"World J Gastroenterol"},{"issue":"5","key":"4846_CR56","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1042\/BST20201201","volume":"50","author":"N Juge","year":"2022","unstructured":"Juge N (2022) Relationship between mucosa-associated gut microbiota and human diseases. Biochem Soc Trans 50(5):1225\u20131236. https:\/\/doi.org\/10.1042\/BST20201201","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"4846_CR57","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/imr.12567","volume":"279","author":"JM Pickard","year":"2017","unstructured":"Pickard JM, Zeng MY, Caruso R, N\u00fa\u00f1ez G (2017) Gut microbiota, Role in pathogen colonization, immune responses, and inflammatory disease. Immunol Rev 279(1):70\u201389. https:\/\/doi.org\/10.1111\/imr.12567","journal-title":"Immunol Rev"},{"key":"4846_CR58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jconrel.2022.10.006","volume":"352","author":"KB Japiassu","year":"2022","unstructured":"Japiassu KB, Fay F, Marengo A, Louaguenouni Y, Cailleau C, Denis S et al (2022) Interplay between mucus mobility and alveolar macrophage targeting of surface-modified liposomes. J Control Release 352:15\u201324. https:\/\/doi.org\/10.1016\/j.jconrel.2022.10.006","journal-title":"J Control Release"},{"issue":"6","key":"4846_CR59","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1208\/s12249-022-02327-4","volume":"23","author":"L Sun","year":"2022","unstructured":"Sun L, Nie X, Lu W, Zhang Q, Fang W, Gao S et al (2022) Mucus-Penetrating Alginate-Chitosan Nanoparticles Loaded with Berberine Hydrochloride for Oral Delivery to the Inflammation Site of Ulcerative Colitis. AAPS PharmSciTech 23(6):179. https:\/\/doi.org\/10.1208\/s12249-022-02327-4","journal-title":"AAPS PharmSciTech"},{"key":"4846_CR60","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jconrel.2023.10.039","volume":"364","author":"W Cheng","year":"2023","unstructured":"Cheng W, Zhou X, Jin C, Wu J, Xia Y, Lu M et al (2023) Acid-base transformative HADLA micelles alleviate colitis by restoring adaptive immunity and gut microbiome. J Control Release 364:283\u2013296. https:\/\/doi.org\/10.1016\/j.jconrel.2023.10.039","journal-title":"J Control Release"},{"issue":"9","key":"4846_CR61","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1128\/aem.61.9.3202-3207.1995","volume":"61","author":"WE Moore","year":"1995","unstructured":"Moore WE, Moore LH (1995) Intestinal floras of populations that have a high risk of colon cancer. Appl Environ Microbiol 61(9):3202\u20133207. https:\/\/doi.org\/10.1128\/aem.61.9.3202-3207.1995","journal-title":"Appl Environ Microbiol"},{"issue":"30","key":"4846_CR62","doi-asserted-by":"publisher","first-page":"49574","DOI":"10.18632\/oncotarget.17319","volume":"8","author":"YJ Zhou","year":"2017","unstructured":"Zhou YJ, Zhao DD, Liu H, Chen HT, Li JJ, Mu XQ et al (2017) Cancer killers in the human gut microbiota, diverse phylogeny and broad spectra. Oncotarget 8(30):49574\u201349591. https:\/\/doi.org\/10.18632\/oncotarget.17319","journal-title":"Oncotarget"},{"issue":"6","key":"4846_CR63","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1517\/17425247.2012.682148","volume":"9","author":"A Gulbake","year":"2012","unstructured":"Gulbake A, Jain SK (2012) Chitosan, a potential polymer for colon-specific drug delivery system. Expert Opin Drug Deliv 9(6):713\u2013729. https:\/\/doi.org\/10.1517\/17425247.2012.682148","journal-title":"Expert Opin Drug Deliv"},{"issue":"19","key":"4846_CR64","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.3390\/nu14194116","volume":"14","author":"AI \u00c1lvarez-Mercado","year":"2022","unstructured":"\u00c1lvarez-Mercado AI, Plaza-Diaz J (2022) Dietary Polysaccharides as Modulators of the Gut Microbiota Ecosystem: An Update on Their Impact on Health. Nutrients 14(19):4116. https:\/\/doi.org\/10.3390\/nu14194116","journal-title":"Nutrients"},{"issue":"31","key":"4846_CR65","doi-asserted-by":"publisher","first-page":"32013","DOI":"10.18632\/oncotarget.5166","volume":"6","author":"YN Yu","year":"2015","unstructured":"Yu YN, Yu TC, Zhao HJ, Sun TT, Chen HM, Chen HY et al (2015) Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment. Oncotarget 6(31):32013\u201332026. https:\/\/doi.org\/10.18632\/oncotarget.5166","journal-title":"Oncotarget"},{"issue":"17","key":"4846_CR66","doi-asserted-by":"publisher","first-page":"9588","DOI":"10.3390\/ijms23179588","volume":"23","author":"P Zhang","year":"2022","unstructured":"Zhang P (2022) Influence of Foods and Nutrition on the Gut Microbiome and Implications for Intestinal Health. Int J Mol Sci 23(17):9588. https:\/\/doi.org\/10.3390\/ijms23179588","journal-title":"Int J Mol Sci"},{"issue":"12","key":"4846_CR67","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.3390\/ijms22126242","volume":"22","author":"M Candelli","year":"2021","unstructured":"Candelli M, Franza L, Pignataro G, Ojetti V, Covino M, Piccioni A et al (2021) Interaction between Lipopolysaccharide and Gut Microbiota in Inflammatory Bowel Diseases. Int J Mol Sci 22(12):6242. https:\/\/doi.org\/10.3390\/ijms22126242","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4846_CR68","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nri3738","volume":"14","author":"AM Mowat","year":"2014","unstructured":"Mowat AM, Agace WW (2014) Regional specialization within the intestinal immune system. Nat Rev Immunol 14(10):667\u2013685. https:\/\/doi.org\/10.1038\/nri3738","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"4846_CR69","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.3748\/wjg.v13.i10.1477","volume":"13","author":"H Miller","year":"2007","unstructured":"Miller H, Zhang J, Kuolee R, Patel GB, Chen W (2007) Intestinal M cells, the fallible sentinels? World J Gastroenterol 13(10):1477\u20131486. https:\/\/doi.org\/10.3748\/wjg.v13.i10.1477","journal-title":"World J Gastroenterol"},{"key":"4846_CR70","doi-asserted-by":"publisher","first-page":"1416537","DOI":"10.3389\/fcimb.2024.1416537","volume":"14","author":"OA Alfituri","year":"2024","unstructured":"Alfituri OA, Blake R, Jensen K, Mabbott NA, Hope J, Stevens JM (2024) Differential role of M cells in enteroid infection by Mycobacterium avium subsp. paratuberculosis and Salmonella enterica serovar Typhimurium. Front Cell Infect Microbiol 14:1416537. https:\/\/doi.org\/10.3389\/fcimb.2024.1416537","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"4846_CR71","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1124\/dmd.120.000283","volume":"49","author":"K Takayama","year":"2021","unstructured":"Takayama K, Ito K, Matsui A, Yamashita T, Kawakami K, Hirayama D et al (2021) In Vivo Gene Expression Profile of Human Intestinal Epithelial Cells: From the Viewpoint of Drug Metabolism and Pharmacokinetics. Drug Metab Dispos 49(3):221\u2013232. https:\/\/doi.org\/10.1124\/dmd.120.000283","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"4846_CR72","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1208\/s12248-016-9889-y","volume":"18","author":"CR Jones","year":"2016","unstructured":"Jones CR, Hatley OJ, Ungell AL, Hilgendorf C, Peters SA, Rostami-Hodjegan A (2016) Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination. AAPS J 18(3):589\u2013604. https:\/\/doi.org\/10.1208\/s12248-016-9889-y","journal-title":"AAPS J"},{"issue":"11","key":"4846_CR73","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1172\/JCI34007","volume":"117","author":"KE Thummel","year":"2007","unstructured":"Thummel KE (2007) Gut instincts, CYP3A4 and intestinal drug metabolism. J Clin Invest 117(11):3173\u20133176. https:\/\/doi.org\/10.1172\/JCI34007","journal-title":"J Clin Invest"},{"issue":"5","key":"4846_CR74","doi-asserted-by":"publisher","first-page":"624","DOI":"10.2174\/1389200211209050624","volume":"13","author":"Y Li","year":"2012","unstructured":"Li Y, Lu J, Paxton JW (2012) The role of ABC and SLC transporters in the pharmacokinetics of dietary and herbal phytochemicals and their interactions with xenobiotics. Curr Drug Metab 13(5):624\u2013639. https:\/\/doi.org\/10.2174\/1389200211209050624","journal-title":"Curr Drug Metab"},{"issue":"7","key":"4846_CR75","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/carcin\/bgg073","volume":"24","author":"Y Mochida","year":"2003","unstructured":"Mochida Y, Taguchi K, Taniguchi S, Tsuneyoshi M, Kuwano H, Tsuzuki T et al (2003) The role of P-glycoprotein in intestinal tumorigenesis, disruption of mdr1a suppresses polyp formation in Apc(Min\/+) mice. Carcinogenesis 24(7):1219\u20131224. https:\/\/doi.org\/10.1093\/carcin\/bgg073","journal-title":"Carcinogenesis"},{"issue":"28","key":"4846_CR76","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1021\/acs.biochem.5b00018","volume":"54","author":"JW McCormick","year":"2015","unstructured":"McCormick JW, Vogel PD, Wise JG (2015) Multiple Drug Transport Pathways through Human P-Glycoprotein. Biochemistry 54(28):4374\u20134390. https:\/\/doi.org\/10.1021\/acs.biochem.5b00018","journal-title":"Biochemistry"},{"issue":"7","key":"4846_CR77","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2217\/pgs.11.44","volume":"12","author":"F M\u00fcller","year":"2011","unstructured":"M\u00fcller F, Fromm MF (2011) Transporter-mediated drug-drug interactions. Pharmacogenomics 12(7):1017\u20131037. https:\/\/doi.org\/10.2217\/pgs.11.44","journal-title":"Pharmacogenomics"},{"issue":"1","key":"4846_CR78","doi-asserted-by":"publisher","first-page":"183090","DOI":"10.1016\/j.bbamem.2019.183090","volume":"1862","author":"S Thangapandian","year":"2020","unstructured":"Thangapandian S, Kapoor K, Tajkhorshid E (2020) Probing cholesterol binding and translocation in P-glycoprotein. Biochim Biophys Acta Biomembr 1862(1):183090. https:\/\/doi.org\/10.1016\/j.bbamem.2019.183090","journal-title":"Biochim Biophys Acta Biomembr"},{"issue":"10","key":"4846_CR79","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.addr.2012.09.042","volume":"65","author":"M Estudante","year":"2013","unstructured":"Estudante M, Morais JG, Soveral G, Benet LZ (2013) Intestinal drug transporters, an overview. Adv Drug Deliv Rev 65(10):1340\u20131356. https:\/\/doi.org\/10.1016\/j.addr.2012.09.042","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"4846_CR80","doi-asserted-by":"publisher","first-page":"e11278","DOI":"10.1016\/j.heliyon.2022.e11278","volume":"8","author":"KA Patel","year":"2022","unstructured":"Patel KA, Bhatt MH, Hirani RV, Patel VA, Patel VN, Shah GB et al (2022) Assessment of potential drug-drug interactions among outpatients in a tertiary care hospital, focusing on the role of P-glycoprotein and CYP3A4 (retrospective observational study). Heliyon 8(11):e11278. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e11278","journal-title":"Heliyon"},{"key":"4846_CR81","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.112854","author":"M Farrukh","year":"2024","unstructured":"Farrukh M, Shahzadi S, Irfan M (2024) Drug Metabolism: Phase I and Phase II Metabolic Pathways. IntechOpen. https:\/\/doi.org\/10.5772\/intechopen.112854","journal-title":"IntechOpen"},{"issue":"1\u20133","key":"4846_CR82","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/s0169-409x(00)00126-5","volume":"46","author":"VJ Wacher","year":"2001","unstructured":"Wacher VJ, Salphati L, Benet LZ (2001) Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 46(1\u20133):89\u2013102. https:\/\/doi.org\/10.1016\/s0169-409x(00)00126-5","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"4846_CR83","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/biomedicines9101353","volume":"9","author":"WH Talib","year":"2021","unstructured":"Talib WH, Alsayed AR, Barakat M, Abu-Taha MI, Mahmod AI (2021) Targeting Drug Chemo-Resistance in Cancer Using Natural Products. Biomedicines 9(10):1353. https:\/\/doi.org\/10.3390\/biomedicines9101353","journal-title":"Biomedicines"},{"issue":"1","key":"4846_CR84","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/jps.22738","volume":"101","author":"B Wu","year":"2012","unstructured":"Wu B (2012) Pharmacokinetic interplay of phase II metabolism and transport: a theoretical study. J Pharm Sci 101(1):381\u2013393. https:\/\/doi.org\/10.1002\/jps.22738","journal-title":"J Pharm Sci"},{"key":"4846_CR85","doi-asserted-by":"publisher","first-page":"869010","DOI":"10.3389\/fmed.2022.869010","volume":"9","author":"J Li","year":"2022","unstructured":"Li J, Chen D, Shen M (2022) Tumor microenvironment shapes colorectal cancer progression, metastasis, and treatment responses. Front Med (Lausanne) 9:869010. https:\/\/doi.org\/10.3389\/fmed.2022.869010","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"4846_CR86","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.3390\/cancers11081172","volume":"11","author":"L Pedrosa","year":"2019","unstructured":"Pedrosa L, Esposito F, Thomson TM, Maurel J (2019) The tumor microenvironment in colorectal cancer therapy. Cancers (Basel) 11(8):1172. https:\/\/doi.org\/10.3390\/cancers11081172","journal-title":"Cancers (Basel)"},{"key":"4846_CR87","doi-asserted-by":"publisher","first-page":"goac042","DOI":"10.1093\/gastro\/goac042","volume":"10","author":"T Fletcher","year":"2022","unstructured":"Fletcher T, Thompson AJ, Ashrafian H, Darzi A (2022) The measurement and modification of hypoxia in colorectal cancer, overlooked but not forgotten. Gastroenterol Rep (Oxf) 10:goac042. https:\/\/doi.org\/10.1093\/gastro\/goac042","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"4846_CR88","doi-asserted-by":"publisher","first-page":"1753180","DOI":"10.3389\/fcell.2025.1753180","volume":"13","author":"J Han","year":"2026","unstructured":"Han J, Liang W, Li K (2026) Unveiling the tumor microenvironment in colorectal cancer therapeutic resistance. Front Cell Dev Biol 13:1753180. https:\/\/doi.org\/10.3389\/fcell.2025.1753180","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"4846_CR89","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.7150\/jca.108582","volume":"16","author":"J Ran","year":"2025","unstructured":"Ran J, Li F, Zhan L, Jin Y, Dong Q, Li X et al (2025) Hypoxia regulates glycolysis through the HIF-1\u03b1\/BMAL1\/ALDOC axis to reduce oxaliplatin sensitivity in colorectal cancer. J Cancer 16(8):2503\u20132515. https:\/\/doi.org\/10.7150\/jca.108582","journal-title":"J Cancer"},{"issue":"10","key":"4846_CR90","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.ymthe.2019.05.017","volume":"27","author":"K Xu","year":"2019","unstructured":"Xu K, Zhan Y, Yuan Z, Qiu Y, Wang H, Fan G et al (2019) Hypoxia induces drug resistance in colorectal cancer through the HIF-1\u03b1\/miR-338-5p\/IL-6 feedback loop. Mol Ther 27(10):1810\u20131824. https:\/\/doi.org\/10.1016\/j.ymthe.2019.05.017","journal-title":"Mol Ther"},{"issue":"1","key":"4846_CR91","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13046-021-02229-6","volume":"41","author":"S Dong","year":"2022","unstructured":"Dong S, Liang S, Cheng Z, Zhang X, Luo L, Li L et al (2022) ROS\/PI3K\/Akt and Wnt\/\u03b2-catenin signalings activate HIF-1\u03b1-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer. J Exp Clin Cancer Res 41(1):15. https:\/\/doi.org\/10.1186\/s13046-021-02229-6","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"4846_CR92","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13062-024-00478-x","volume":"19","author":"Y Geng","year":"2024","unstructured":"Geng Y, Zheng X, Zhang D, Wei S, Feng J, Wang W et al (2024) CircHIF1A induces cetuximab resistance in colorectal cancer by promoting HIF1\u03b1-mediated glycometabolism alteration. Biol Direct 19(1):36. https:\/\/doi.org\/10.1186\/s13062-024-00478-x","journal-title":"Biol Direct"},{"issue":"1","key":"4846_CR93","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13578-023-00977-w","volume":"13","author":"J Zhang","year":"2023","unstructured":"Zhang J, Zou S, Fang L (2023) Metabolic reprogramming in colorectal cancer, regulatory networks and therapy. Cell Biosci 13(1):25. https:\/\/doi.org\/10.1186\/s13578-023-00977-w","journal-title":"Cell Biosci"},{"key":"4846_CR94","doi-asserted-by":"publisher","first-page":"102065","DOI":"10.1016\/j.redox.2021.102065","volume":"46","author":"M Ying","year":"2021","unstructured":"Ying M, You D, Zhu X, Cai L, Zeng S, Hu X (2021) Lactate and glutamine support NADPH generation in cancer cells under glucose deprived conditions. Redox Biol 46:102065. https:\/\/doi.org\/10.1016\/j.redox.2021.102065","journal-title":"Redox Biol"},{"issue":"6","key":"4846_CR95","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.7150\/thno.82920","volume":"13","author":"K Yang","year":"2023","unstructured":"Yang K, Wang X, Song C, He Z, Wang R, Xu Y et al (2023) The role of lipid metabolic reprogramming in tumor microenvironment. Theranostics 13(6):1774\u20131808. https:\/\/doi.org\/10.7150\/thno.82920","journal-title":"Theranostics"},{"issue":"4","key":"4846_CR96","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s12276-023-00971-9","volume":"55","author":"J Jin","year":"2023","unstructured":"Jin J, Byun JK, Choi YK, Park KG (2023) Targeting glutamine metabolism as a therapeutic strategy for cancer. Exp Mol Med 55(4):706\u2013715. https:\/\/doi.org\/10.1038\/s12276-023-00971-9","journal-title":"Exp Mol Med"},{"issue":"1","key":"4846_CR97","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41420-025-02670-y","volume":"11","author":"X Qiu","year":"2025","unstructured":"Qiu X, Wang A, Wang J, Zhang Z, Tao L (2025) Mitochondrial metabolic reprogramming in colorectal cancer, mechanisms of resistance and future clinical interventions. Cell Death Discov 11(1):375. https:\/\/doi.org\/10.1038\/s41420-025-02670-y","journal-title":"Cell Death Discov"},{"issue":"1\u20133","key":"4846_CR98","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1089\/ars.2022.0127","volume":"39","author":"NJ Lyons","year":"2023","unstructured":"Lyons NJ, Giri R, Begun J, Clark D, Proud D, He Y et al (2023) Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancer. Antioxid Redox Signal 39(1\u20133):186\u2013205. https:\/\/doi.org\/10.1089\/ars.2022.0127","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"4846_CR99","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/s41467-025-56444-2","volume":"16","author":"S Wang","year":"2025","unstructured":"Wang S, Wu X, Bi W, Xu J, Hou L, Li G et al (2025) ROS-induced cytosolic release of mitochondrial PGAM5 promotes colorectal cancer progression by interacting with MST3. Nat Commun 16(1):1406. https:\/\/doi.org\/10.1038\/s41467-025-56444-2","journal-title":"Nat Commun"},{"issue":"5","key":"4846_CR100","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3390\/antiox10050743","volume":"10","author":"DY Lee","year":"2021","unstructured":"Lee DY, Song MY, Kim EH (2021) Role of oxidative stress and Nrf2\/KEAP1 signaling in colorectal cancer, mechanisms and therapeutic perspectives with phytochemicals. Antioxid (Basel) 10(5):743. https:\/\/doi.org\/10.3390\/antiox10050743","journal-title":"Antioxid (Basel)"},{"key":"4846_CR101","doi-asserted-by":"publisher","first-page":"5985","DOI":"10.2147\/JIR.S479794","volume":"17","author":"M Hu","year":"2024","unstructured":"Hu M, Yuan L, Zhu J (2024) The dual role of NRF2 in colorectal cancer, targeting NRF2 as a potential therapeutic approach. J Inflamm Res 17:5985\u20136004. https:\/\/doi.org\/10.2147\/JIR.S479794","journal-title":"J Inflamm Res"},{"issue":"1","key":"4846_CR102","doi-asserted-by":"publisher","first-page":"e160886","DOI":"10.5812\/ijpr-160886","volume":"24","author":"J Wang","year":"2025","unstructured":"Wang J, Lu Y, Wang Z, Wei P (2025) Cancer-associated fibroblasts enhance oxaliplatin resistance in colorectal cancer cells via paracrine IL-6, an in vitro study. Iran J Pharm Res 24(1):e160886. https:\/\/doi.org\/10.5812\/ijpr-160886","journal-title":"Iran J Pharm Res"},{"issue":"6","key":"4846_CR103","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/ijc.32608","volume":"146","author":"X Deng","year":"2020","unstructured":"Deng X, Ruan H, Zhang X, Xu X, Zhu Y, Peng H et al (2020) Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells. Int J Cancer 146(6):1700\u20131716. https:\/\/doi.org\/10.1002\/ijc.32608","journal-title":"Int J Cancer"},{"issue":"4","key":"4846_CR104","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.21037\/tcr.2020.03.03","volume":"9","author":"Y Xiao","year":"2020","unstructured":"Xiao Y, Hu F, Li M, Mo L, Xu C, Wang X et al (2020) Interaction between linc01615 and miR-491-5p regulates the survival and metastasis of colorectal cancer cells. Transl Cancer Res 9(4):2638\u20132647. https:\/\/doi.org\/10.21037\/tcr.2020.03.03","journal-title":"Transl Cancer Res"},{"key":"4846_CR105","doi-asserted-by":"publisher","first-page":"116171","DOI":"10.1016\/j.taap.2022.116171","volume":"450","author":"C Galindo-Pumari\u00f1o","year":"2022","unstructured":"Galindo-Pumari\u00f1o C, Collado M, Castillo ME, Barqu\u00edn J, Romio E, Larriba MJ et al (2022) SNAI1-expressing fibroblasts and derived extracellular matrix as mediators of drug resistance in colorectal cancer patients. Toxicol Appl Pharmacol 450:116171. https:\/\/doi.org\/10.1016\/j.taap.2022.116171","journal-title":"Toxicol Appl Pharmacol"},{"issue":"5","key":"4846_CR106","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.55730\/1300-0144.5494","volume":"52","author":"M Besler","year":"2022","unstructured":"Besler M, Dost FS, \u015eenler F\u00c7, K\u0131rm\u0131z\u0131 BA, Sava\u015f B, Akbulut H (2022) The role of pericytes on the efficacy of bevacizumab in colorectal cancer. Turk J Med Sci 52(5):1543\u20131550. https:\/\/doi.org\/10.55730\/1300-0144.5494","journal-title":"Turk J Med Sci"},{"issue":"1","key":"4846_CR107","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12935-022-02599-7","volume":"22","author":"B Feng","year":"2022","unstructured":"Feng B, Wu J, Shen B, Jiang F, Feng J (2022) Cancer-associated fibroblasts and resistance to anticancer therapies, status, mechanisms, and countermeasures. Cancer Cell Int 22(1):166. https:\/\/doi.org\/10.1186\/s12935-022-02599-7","journal-title":"Cancer Cell Int"},{"issue":"9","key":"4846_CR108","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.3390\/biomedicines11092361","volume":"11","author":"N Shakhpazyan","year":"2023","unstructured":"Shakhpazyan N, Mikhaleva L, Bedzhanyan A, Gioeva Z, Sadykhov N, Mikhalev A et al (2023) Cellular and molecular mechanisms of the tumor stroma in colorectal cancer, insights into disease progression and therapeutic targets. Biomedicines 11(9):2361. https:\/\/doi.org\/10.3390\/biomedicines11092361","journal-title":"Biomedicines"},{"issue":"7","key":"4846_CR109","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/cancers17071098","volume":"17","author":"M El Hage","year":"2025","unstructured":"El Hage M, Su Z, Linnebacher M (2025) Addressing Challenges in Targeted Therapy for Metastatic Colorectal Cancer. Cancers (Basel) 17(7):1098. https:\/\/doi.org\/10.3390\/cancers17071098","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4846_CR110","doi-asserted-by":"publisher","first-page":"103409","DOI":"10.1016\/j.drudis.2022.103409","volume":"28","author":"S Dewanjee","year":"2023","unstructured":"Dewanjee S, Chakraborty P, Bhattacharya H, Singh SK, Dua K, Dey A et al (2023) Recent advances in flavonoid-based nanocarriers as an emerging drug delivery approach for cancer chemotherapy. Drug Discov Today 28(1):103409. https:\/\/doi.org\/10.1016\/j.drudis.2022.103409","journal-title":"Drug Discov Today"},{"issue":"16","key":"4846_CR111","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1200\/JCO.19.00281","volume":"37","author":"C Lieu","year":"2019","unstructured":"Lieu C, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S et al (2019) Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer, ASCO Clinical Practice Guideline. J Clin Oncol 37(16):1436\u20131447. https:\/\/doi.org\/10.1200\/JCO.19.00281","journal-title":"J Clin Oncol"},{"key":"4846_CR112","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40959-019-0048-3","volume":"5","author":"C Yuan","year":"2019","unstructured":"Yuan C, Parekh H, Allegra C, George TJ, Starr JS (2019) 5-FU induced cardiotoxicity, case series and review of the literature. Cardiooncology 5:13. https:\/\/doi.org\/10.1186\/s40959-019-0048-3","journal-title":"Cardiooncology"},{"issue":"2","key":"4846_CR113","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cclet.2021.08.090","volume":"33","author":"Y Song","year":"2022","unstructured":"Song Y, Huang Y, Zhou F, Ding J, Zhou W (2022) Macrophage-targeted nanomedicine for chronic diseases immunotherapy. Chin Chem Lett 33(2):597\u2013612. https:\/\/doi.org\/10.1016\/j.cclet.2021.08.090","journal-title":"Chin Chem Lett"},{"issue":"1","key":"4846_CR114","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12951-022-01605-4","volume":"20","author":"S Waheed","year":"2022","unstructured":"Waheed S, Li Z, Zhang F, Chiarini A, Armato U, Wu J (2022) Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. J Nanobiotechnol 20(1):395. https:\/\/doi.org\/10.1186\/s12951-022-01605-4","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"4846_CR115","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12943-025-02368-w","volume":"24","author":"KM Abdullah","year":"2025","unstructured":"Abdullah KM, Sharma G, Singh AP, Siddiqui JA (2025) Nanomedicine in Cancer Therapeutics, Current Perspectives from Bench to Bedside. Mol Cancer 24(1):169. https:\/\/doi.org\/10.1186\/s12943-025-02368-w","journal-title":"Mol Cancer"},{"key":"4846_CR116","doi-asserted-by":"publisher","first-page":"114267","DOI":"10.1016\/j.ejpb.2024.114267","volume":"198","author":"D Patel","year":"2024","unstructured":"Patel D, Sethi N, Patel P, Shah S, Patel K (2024) Exploring the potential of P-glycoprotein inhibitors in the targeted delivery of anti-cancer drugs, A comprehensive review. Eur J Pharm Biopharm 198:114267. https:\/\/doi.org\/10.1016\/j.ejpb.2024.114267","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"4846_CR117","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1039\/d0cs01127d","volume":"50","author":"M Sousa de Almeida","year":"2021","unstructured":"Sousa de Almeida M, Susnik E, Drasler B, Taladriz-Blanco P, Petri-Fink A, Rothen-Rutishauser B (2021) Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine. Chem Soc Rev 50(9):5397\u20135434. https:\/\/doi.org\/10.1039\/d0cs01127d","journal-title":"Chem Soc Rev"},{"issue":"1","key":"4846_CR118","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1080\/10717544.2017.1410256","volume":"24","author":"SS Qi","year":"2017","unstructured":"Qi SS, Sun JH, Yu HH, Yu SQ (2017) Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy. Drug Deliv 24(1):1909\u20131926. https:\/\/doi.org\/10.1080\/10717544.2017.1410256","journal-title":"Drug Deliv"},{"key":"4846_CR119","doi-asserted-by":"publisher","first-page":"0148","DOI":"10.34133\/research.0148","volume":"6","author":"C Qiu","year":"2023","unstructured":"Qiu C, Xia F, Zhang J, Shi Q, Meng Y, Wang C et al (2023) Advanced strategies for overcoming endosomal\/lysosomal barrier in nanodrug delivery. Res (Wash D C) 6:0148. https:\/\/doi.org\/10.34133\/research.0148","journal-title":"Res (Wash D C)"},{"key":"4846_CR120","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.2147\/IJN.S303832","volume":"16","author":"KS Allemailem","year":"2021","unstructured":"Allemailem KS, Almatroudi A, Alsahli MA, Aljaghwani A, El-Kady AM, Rahmani AH et al (2021) Novel strategies for disrupting cancer-cell functions with mitochondria-targeted antitumor drug-loaded nanoformulations. Int J Nanomed 16:3907\u20133936. https:\/\/doi.org\/10.2147\/IJN.S303832","journal-title":"Int J Nanomed"},{"issue":"3","key":"4846_CR121","doi-asserted-by":"publisher","first-page":"101036","DOI":"10.1016\/j.ajps.2025.10103","volume":"20","author":"M Mazloomi","year":"2025","unstructured":"Mazloomi M, Doustmihan A, Alimohammadvand S, Hamishehkar H, Hamblin MR, Jahanban Esfahlan R (2025) Advanced drug delivery platforms target cancer stem cells. Asian J Pharm Sci 20(3):101036. https:\/\/doi.org\/10.1016\/j.ajps.2025.10103","journal-title":"Asian J Pharm Sci"},{"issue":"10","key":"4846_CR122","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3390\/inorganics13100337","volume":"13","author":"Z Jiang","year":"2025","unstructured":"Jiang Z, Xiang H, Tang X (2025) Smart inorganic nanomaterials for tumor microenvironment modulation. Inorganics 13(10):337. https:\/\/doi.org\/10.3390\/inorganics13100337","journal-title":"Inorganics"},{"issue":"15","key":"4846_CR123","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1080\/17435889.2024.2350356","volume":"19","author":"A Kumar","year":"2024","unstructured":"Kumar A, Vaiphei KK, Singh N, Datta Chigurupati SP, Paliwal SR, Paliwal R et al (2024) Nanomedicine for colon-targeted drug delivery, strategies focusing on inflammatory bowel disease and colon cancer. Nanomed (Lond) 19(15):1347\u20131368. https:\/\/doi.org\/10.1080\/17435889.2024.2350356","journal-title":"Nanomed (Lond)"},{"issue":"3","key":"4846_CR124","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3390\/biomedicines13030642","volume":"13","author":"SH Shaham","year":"2025","unstructured":"Shaham SH, Vij P, Tripathi MK (2025) Advances in targeted and chemotherapeutic strategies for colorectal cancer: current insights and future directions. Biomedicines 13(3):642. https:\/\/doi.org\/10.3390\/biomedicines13030642","journal-title":"Biomedicines"},{"issue":"3 Suppl 5","key":"4846_CR125","first-page":"16","volume":"15","author":"RB Diasio","year":"2001","unstructured":"Diasio RB (2001) Current status of oral chemotherapy for colorectal cancer. Oncol (Williston Park) 15(3 Suppl 5):16\u201320","journal-title":"Oncol (Williston Park)"},{"key":"4846_CR126","doi-asserted-by":"publisher","first-page":"1399998","DOI":"10.3389\/fphar.2024.1399998","volume":"15","author":"Y Hu","year":"2024","unstructured":"Hu Y, Du Y, Qiu Z, Zhu C, Wang J, Liang T et al (2024) Signal mining and analysis of trifluridine\/tipiracil adverse events based on real-world data from the FAERS database. Front Pharmacol 15:1399998. https:\/\/doi.org\/10.3389\/fphar.2024.1399998","journal-title":"Front Pharmacol"},{"issue":"Pt 1","key":"4846_CR127","doi-asserted-by":"publisher","first-page":"112155","DOI":"10.1016\/j.colsurfb.2021.112155","volume":"209","author":"B Lu","year":"2022","unstructured":"Lu B, Jan Hendriks A, Nolte TM (2022) A generic model based on the properties of nanoparticles and cells for predicting cellular uptake. Colloids Surf B Biointerfaces 209(Pt 1):112155. https:\/\/doi.org\/10.1016\/j.colsurfb.2021.112155","journal-title":"Colloids Surf B Biointerfaces"},{"key":"4846_CR128","doi-asserted-by":"publisher","first-page":"102278","DOI":"10.1016\/j.mtbio.2025.102278","volume":"35","author":"X Wang","year":"2025","unstructured":"Wang X, Sun K, Dong J, Ge Y, Liu H, Jin X et al (2025) Carrier-free nanoparticles based on natural products trigger dual synergy and attenuation for enhanced phototherapy of liver cancer. Mater Today Bio 35:102278. https:\/\/doi.org\/10.1016\/j.mtbio.2025.102278","journal-title":"Mater Today Bio"},{"issue":"2","key":"4846_CR129","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3390\/cells11020249","volume":"11","author":"TM Lwin","year":"2022","unstructured":"Lwin TM, Turner MA, Amirfakhri S, Nishino H, Hoffman RM, Bouvet M (2022) Fluorescence Molecular Targeting of Colon Cancer to Visualize the Invisible. Cells 11(2):249. https:\/\/doi.org\/10.3390\/cells11020249","journal-title":"Cells"},{"key":"4846_CR130","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.addr.2017.09.020","volume":"124","author":"F Ara\u00fajo","year":"2018","unstructured":"Ara\u00fajo F, Martins C, Azevedo C, Sarmento B (2018) Chemical modification of drug molecules as strategy to reduce interactions with mucus. Adv Drug Deliv Rev 124:98\u2013106. https:\/\/doi.org\/10.1016\/j.addr.2017.09.020","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"4846_CR131","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s12195-022-00740-0","volume":"15","author":"J McCright","year":"2022","unstructured":"McCright J, Sinha A, Maisel K (2022) Generating an in vitro gut model with physiologically relevant biophysical mucus properties. Cell Mol Bioeng 15(5):479\u2013491. https:\/\/doi.org\/10.1007\/s12195-022-00740-0","journal-title":"Cell Mol Bioeng"},{"issue":"1","key":"4846_CR132","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1186\/s12951-024-02930-6","volume":"22","author":"Y Wang","year":"2024","unstructured":"Wang Y, Mo Y, Sun Y, Li J, An Y, Feng N et al (2024) Intestinal nanoparticle delivery and cellular response: a review of the bidirectional nanoparticle-cell interplay in mucosa based on physicochemical properties. J Nanobiotechnol 22(1):669. https:\/\/doi.org\/10.1186\/s12951-024-02930-6","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"4846_CR133","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1021\/acs.molpharmaceut.9b00971","volume":"17","author":"S Zhou","year":"2020","unstructured":"Zhou S, Deng H, Zhang Y, Wu P, He B, Dai W et al (2020) Thiolated nanoparticles overcome the mucus barrier and epithelial barrier for oral delivery of insulin. Mol Pharm 17(1):239\u2013250. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00971","journal-title":"Mol Pharm"},{"issue":"1","key":"4846_CR134","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12951-022-01539-x","volume":"20","author":"DA Subramanian","year":"2022","unstructured":"Subramanian DA, Langer R, Traverso G (2022) Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems. J Nanobiotechnol 20(1):362. https:\/\/doi.org\/10.1186\/s12951-022-01539-x","journal-title":"J Nanobiotechnol"},{"issue":"6","key":"4846_CR135","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3390\/biom12060784","volume":"12","author":"F Rodr\u00edguez","year":"2022","unstructured":"Rodr\u00edguez F, Caruana P, De la Fuente N, Espa\u00f1ol P, G\u00e1mez M, Balart J et al (2022) Nano-Based Approved Pharmaceuticals for Cancer Treatment, Present and Future Challenges. Biomolecules 12(6):784. https:\/\/doi.org\/10.3390\/biom12060784","journal-title":"Biomolecules"},{"issue":"6","key":"4846_CR136","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1080\/21691401.2017.1366338","volume":"46","author":"K Rajpoot","year":"2018","unstructured":"Rajpoot K, Jain SK (2018) Colorectal cancer-targeted delivery of oxaliplatin via folic acid-grafted solid lipid nanoparticles, preparation, optimization, and in vitro evaluation. Artif Cells Nanomed Biotechnol 46(6):1236\u20131247. https:\/\/doi.org\/10.1080\/21691401.2017.1366338","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"7","key":"4846_CR137","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/02652048.2019.1665723","volume":"36","author":"K Rajpoot","year":"2019","unstructured":"Rajpoot K, Jain SK (2019) Irinotecan hydrochloride trihydrate loaded folic acid-tailored solid lipid nanoparticles for targeting colorectal cancer, development, characterization, and in vitro cytotoxicity study using HT-29 cells. J Microencapsul 36(7):659\u2013676. https:\/\/doi.org\/10.1080\/02652048.2019.1665723","journal-title":"J Microencapsul"},{"key":"4846_CR138","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ijbiomac.2020.02.132","volume":"151","author":"K Rajpoot","year":"2020","unstructured":"Rajpoot K, Jain SK (2020) Oral delivery of pH-responsive alginate microbeads incorporating folic acid-grafted solid lipid nanoparticles exhibits enhanced targeting effect against colorectal cancer: A dual-targeted approach. Int J Biol Macromol 151:830\u2013844. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.02.132","journal-title":"Int J Biol Macromol"},{"key":"4846_CR139","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.biomaterials.2019.01.019","volume":"197","author":"MY Shen","year":"2019","unstructured":"Shen MY, Liu TI, Yu TW, Kv R, Chiang WH, Tsai YC et al (2019) Hierarchically targetable polysaccharide-coated solid lipid nanoparticles as an oral chemo\/thermotherapy delivery system for local treatment of colon cancer. Biomaterials 197:86\u2013100. https:\/\/doi.org\/10.1016\/j.biomaterials.2019.01.019","journal-title":"Biomaterials"},{"key":"4846_CR140","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejpb.2023.02.016","volume":"185","author":"D Xia","year":"2023","unstructured":"Xia D, Hu C, Hou Y (2023) Regorafenib loaded self-assembled lipid-based nanocarrier for colorectal cancer treatment via lymphatic absorption. Eur J Pharm Biopharm 185:165\u2013176. https:\/\/doi.org\/10.1016\/j.ejpb.2023.02.016","journal-title":"Eur J Pharm Biopharm"},{"key":"4846_CR141","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ijbiomac.2022.05.060","volume":"211","author":"NA Bhaskaran","year":"2022","unstructured":"Bhaskaran NA, Jitta SR, Salwa, Cheruku S, Kumar N, Kumar L (2022) Orally delivered solid lipid nanoparticles of irinotecan coupled with chitosan surface modification to treat colon cancer, Preparation, in-vitro and in-vivo evaluations. Int J Biol Macromol 211:301\u2013315. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.05.060","journal-title":"Int J Biol Macromol"},{"issue":"20","key":"4846_CR142","doi-asserted-by":"publisher","first-page":"e2201140","DOI":"10.1002\/adhm.202201140","volume":"11","author":"IL Lu","year":"2022","unstructured":"Lu IL, Yu TW, Liu TI, Chen HH, Yang YC, Lo CL et al (2022) Microfluidized Dextran Microgels Loaded with Cisplatin\/SPION Lipid Nanotherapeutics for Local Colon Cancer Treatment via Oral Administration. Adv Healthc Mater 11(20):e2201140. https:\/\/doi.org\/10.1002\/adhm.202201140","journal-title":"Adv Healthc Mater"},{"key":"4846_CR143","doi-asserted-by":"publisher","DOI":"10.1039\/d5nr01337b","author":"A Xia","year":"2025","unstructured":"Xia A, Yuan W, Xu S, Wu T, Yan W, Cao Y (2025) A prebiotic inulin derivative-containing liposome for oral berberine delivery improves the orthotopic colorectal cancer chemotherapy. Nanoscale. https:\/\/doi.org\/10.1039\/d5nr01337b","journal-title":"Nanoscale"},{"key":"4846_CR144","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.biomaterials.2015.01.014","volume":"48","author":"B Xiao","year":"2015","unstructured":"Xiao B, Zhang M, Viennois E, Zhang Y, Wei N, Baker MT et al (2015) Inhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles. Biomaterials 48:147\u2013160. https:\/\/doi.org\/10.1016\/j.biomaterials.2015.01.014","journal-title":"Biomaterials"},{"issue":"6","key":"4846_CR145","doi-asserted-by":"publisher","first-page":"5253","DOI":"10.1021\/acsnano.7b08499","volume":"12","author":"B Xiao","year":"2018","unstructured":"Xiao B, Viennois E, Chen Q, Wang L, Han MK, Zhang Y et al (2018) Silencing of Intestinal Glycoprotein CD98 by Orally Targeted Nanoparticles Enhances Chemosensitization of Colon Cancer. ACS Nano 12(6):5253\u20135265. https:\/\/doi.org\/10.1021\/acsnano.7b08499","journal-title":"ACS Nano"},{"issue":"1","key":"4846_CR146","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/21691401.2021.1907393","volume":"49","author":"F Sharifi","year":"2021","unstructured":"Sharifi F, Jahangiri M, Ebrahimnejad P (2021) Synthesis of novel polymeric nanoparticles (methoxy-polyethylene glycol-chitosan\/hyaluronic acid) containing 7-ethyl-10-hydroxycamptothecin for colon cancer therapy, in vitro, ex vivo and in vivo investigation. Artif Cells Nanomed Biotechnol 49(1):367\u2013380. https:\/\/doi.org\/10.1080\/21691401.2021.1907393","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"4846_CR147","doi-asserted-by":"publisher","first-page":"121440","DOI":"10.1016\/j.biomaterials.2022.121440","volume":"283","author":"Y Hou","year":"2022","unstructured":"Hou Y, Jin J, Duan H, Liu C, Chen L, Huang W et al (2022) Targeted therapeutic effects of oral inulin-modified double-layered nanoparticles containing chemotherapeutics on orthotopic colon cancer. Biomaterials 283:121440. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121440","journal-title":"Biomaterials"},{"key":"4846_CR148","doi-asserted-by":"publisher","first-page":"119468","DOI":"10.1016\/j.ijpharm.2020.119468","volume":"584","author":"S \u00dcnal","year":"2020","unstructured":"\u00dcnal S, Akta\u015f Y, Benito JM, Bilensoy E (2020) Cyclodextrin nanoparticle bound oral camptothecin for colorectal cancer: Formulation development and optimization. Int J Pharm 584:119468. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119468","journal-title":"Int J Pharm"},{"key":"4846_CR149","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejpb.2021.10.010","volume":"169","author":"S \u00dcnal","year":"2021","unstructured":"\u00dcnal S, Can \u00d6zt\u00fcrk S, Bilgi\u00e7 E, Yan\u0131k H, Korkusuz P, Akta\u015f Y et al (2021) Therapeutic efficacy and gastrointestinal biodistribution of polycationic nanoparticles for oral camptothecin delivery in early and late-stage colorectal tumor-bearing animal model. Eur J Pharm Biopharm 169:168\u2013177. https:\/\/doi.org\/10.1016\/j.ejpb.2021.10.010","journal-title":"Eur J Pharm Biopharm"},{"issue":"12","key":"4846_CR150","doi-asserted-by":"publisher","first-page":"181027","DOI":"10.1098\/rsos.181027","volume":"5","author":"W Liu","year":"2018","unstructured":"Liu W, Zhu Y, Wang F, Li X, Liu X, Pang J et al (2018) Galactosylated chitosan-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery. R Soc Open Sci 5(12):181027. https:\/\/doi.org\/10.1098\/rsos.181027","journal-title":"R Soc Open Sci"},{"issue":"8","key":"4846_CR151","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2217\/nnm.12.176","volume":"8","author":"SR Satapathy","year":"2013","unstructured":"Satapathy SR, Mohapatra P, Preet R, Das D, Sarkar B, Choudhuri T et al (2013) Silver-based nanoparticles induce apoptosis in human colon cancer cells mediated through p53. Nanomed (Lond) 8(8):1307\u20131322. https:\/\/doi.org\/10.2217\/nnm.12.176","journal-title":"Nanomed (Lond)"},{"issue":"10","key":"4846_CR152","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/mt.2016.159","volume":"24","author":"M Zhang","year":"2016","unstructured":"Zhang M, Xiao B, Wang H, Han MK, Zhang Z, Viennois E et al (2016) Edible Ginger-derived Nano-lipids Loaded with Doxorubicin as a Novel Drug-delivery Approach for Colon Cancer Therapy. Mol Ther 24(10):1783\u20131796. https:\/\/doi.org\/10.1038\/mt.2016.159","journal-title":"Mol Ther"},{"issue":"7","key":"4846_CR153","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.3390\/nano10071424","volume":"10","author":"C Yang","year":"2020","unstructured":"Yang C, Merlin D (2020) Lipid-Based Drug Delivery Nanoplatforms for Colorectal Cancer Therapy. Nanomaterials (Basel) 10(7):1424. https:\/\/doi.org\/10.3390\/nano10071424","journal-title":"Nanomaterials (Basel)"},{"issue":"4","key":"4846_CR154","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00280-007-0509-5","volume":"61","author":"AR Clamp","year":"2008","unstructured":"Clamp AR, Sch\u00f6ffski P, Valle JW, Wilson RH, Marreaud S, Govaerts AS et al (2008) A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 61(4):579\u2013585. https:\/\/doi.org\/10.1007\/s00280-007-0509-5","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"4846_CR155","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00280-006-0235-4","volume":"58","author":"T Dragovich","year":"2006","unstructured":"Dragovich T, Mendelson D, Kurtin S, Richardson K, Von Hoff D, Hoos A (2006) A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother Pharmacol 58(6):759\u2013764. https:\/\/doi.org\/10.1007\/s00280-006-0235-4","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"4846_CR156","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/pharmaceutics9020012","volume":"9","author":"U Bulbake","year":"2017","unstructured":"Bulbake U, Doppalapudi S, Kommineni N, Khan W (2017) Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics 9(2):12. https:\/\/doi.org\/10.3390\/pharmaceutics9020012","journal-title":"Pharmaceutics"},{"issue":"3","key":"4846_CR157","doi-asserted-by":"publisher","first-page":"e10143","DOI":"10.1002\/btm2.10143","volume":"4","author":"AC Anselmo","year":"2019","unstructured":"Anselmo AC, Mitragotri S (2019) Nanoparticles in the clinic: An update. Bioeng Transl Med 4(3):e10143. https:\/\/doi.org\/10.1002\/btm2.10143","journal-title":"Bioeng Transl Med"},{"key":"4846_CR158","doi-asserted-by":"publisher","first-page":"119351","DOI":"10.1016\/j.carbpol.2022.119351","volume":"288","author":"N Kulkarni","year":"2022","unstructured":"Kulkarni N, Jain P, Shindikar A, Suryawanshi P, Thorat N (2022) Advances in the colon-targeted chitosan based multiunit drug delivery systems for the treatment of inflammatory bowel disease. Carbohydr Polym 288:119351. https:\/\/doi.org\/10.1016\/j.carbpol.2022.119351","journal-title":"Carbohydr Polym"},{"issue":"8","key":"4846_CR159","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2174\/1567201817666200527133719","volume":"17","author":"S Chadha","year":"2020","unstructured":"Chadha S, Kumar A, Srivastava SA, Behl T, Ranjan R (2020) Inulin as a delivery vehicle for targeting colon-specific cancer. Curr Drug Deliv 17(8):651\u2013674. https:\/\/doi.org\/10.2174\/1567201817666200527133719","journal-title":"Curr Drug Deliv"},{"issue":"8","key":"4846_CR160","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3390\/polym16081159","volume":"16","author":"G Satchanska","year":"2024","unstructured":"Satchanska G, Davidova S, Petrov PD (2024) Natural and Synthetic Polymers for Biomedical and Environmental Applications. Polym (Basel) 16(8):1159. https:\/\/doi.org\/10.3390\/polym16081159","journal-title":"Polym (Basel)"},{"issue":"13","key":"4846_CR161","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1039\/d0bm00556h","volume":"8","author":"A Bai\u00e3o","year":"2020","unstructured":"Bai\u00e3o A, Sousa F, Oliveira AV, Oliveira C, Sarmento B (2020) Effective intracellular delivery of bevacizumab via PEGylated polymeric nanoparticles targeting the CD44v6 receptor in colon cancer cells. Biomater Sci 8(13):3720\u20133729. https:\/\/doi.org\/10.1039\/d0bm00556h","journal-title":"Biomater Sci"},{"issue":"Pt B","key":"4846_CR162","doi-asserted-by":"publisher","first-page":"122935","DOI":"10.1016\/j.carbpol.2024.122935","volume":"348","author":"D Bhirud","year":"2025","unstructured":"Bhirud D, Bhattacharya S, Raval H, Sangave PC, Gupta GL, Paraskar G et al (2025) Chitosan nanoparticles of imatinib mesylate coated with TPGS for the treatment of colon cancer, In-vivo & in-vitro studies. Carbohydr Polym 348(Pt B):122935. https:\/\/doi.org\/10.1016\/j.carbpol.2024.122935","journal-title":"Carbohydr Polym"},{"issue":"9","key":"4846_CR163","doi-asserted-by":"publisher","first-page":"108192","DOI":"10.1016\/j.cclet.2023.108192","volume":"34","author":"L Dong","year":"2023","unstructured":"Dong L, Ding J, Zhu L, Liu Y, Gao X, Zhou W (2023) Copper carbonate nanoparticles as an effective biomineralized carrier to load macromolecular drugs for multimodal therapy. Chin Chem Lett 34(9):108192. https:\/\/doi.org\/10.1016\/j.cclet.2023.108192","journal-title":"Chin Chem Lett"},{"issue":"7","key":"4846_CR164","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1002\/mnfr.201300729","volume":"58","author":"J Mu","year":"2014","unstructured":"Mu J, Zhuang X, Wang Q, Jiang H, Deng ZB, Wang B et al (2014) Interspecies communication between plant and mouse gut host cells through edible plant derived exosome-like nanoparticles. Mol Nutr Food Res 58(7):1561\u20131573. https:\/\/doi.org\/10.1002\/mnfr.201300729","journal-title":"Mol Nutr Food Res"},{"key":"4846_CR165","doi-asserted-by":"publisher","first-page":"881641","DOI":"10.3389\/fonc.2022.881641","volume":"12","author":"OA Ojo","year":"2022","unstructured":"Ojo OA, Adeyemo TR, Rotimi D, Batiha GE, Mostafa-Hedeab G, Iyobhebhe ME et al (2022) Anticancer Properties of Curcumin Against Colorectal Cancer: A Review. Front Oncol 12:881641. https:\/\/doi.org\/10.3389\/fonc.2022.881641","journal-title":"Front Oncol"},{"issue":"6","key":"4846_CR166","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/17425247.2024.2375400","volume":"21","author":"Y He","year":"2024","unstructured":"He Y, Wang Y, Wang L, Jiang W, Wilhelm S (2024) Understanding nanoparticle-liver interactions in nanomedicine. Expert Opin Drug Deliv 21(6):829\u2013843. https:\/\/doi.org\/10.1080\/17425247.2024.2375400","journal-title":"Expert Opin Drug Deliv"},{"issue":"8","key":"4846_CR167","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1128\/IAI.00187-08","volume":"76","author":"GO Canny","year":"2008","unstructured":"Canny GO, McCormick BA (2008) Bacteria in the intestine, helpful residents or enemies from within? Infect Immun 76(8):3360\u20133373. https:\/\/doi.org\/10.1128\/IAI.00187-08","journal-title":"Infect Immun"},{"issue":"4","key":"4846_CR168","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.3390\/ijms22041942","volume":"22","author":"M Ghebretatios","year":"2021","unstructured":"Ghebretatios M, Schaly S, Prakash S (2021) Nanoparticles in the food industry and their impact on human gut microbiome and diseases. Int J Mol Sci 22(4):1942. https:\/\/doi.org\/10.3390\/ijms22041942","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4846_CR169","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3390\/toxics11040384","volume":"11","author":"Y Ma","year":"2023","unstructured":"Ma Y, Zhang J, Yu N, Shi J, Zhang Y, Chen Z et al (2023) Effect of nanomaterials on gut microbiota. Toxics 11(4):384. https:\/\/doi.org\/10.3390\/toxics11040384","journal-title":"Toxics"},{"issue":"21","key":"4846_CR170","doi-asserted-by":"publisher","first-page":"e1907687","DOI":"10.1002\/smll.201907687","volume":"16","author":"L Laloux","year":"2020","unstructured":"Laloux L, Kastrati D, Cambier S, Gutleb AC, Schneider YJ (2020) The Food Matrix and the Gastrointestinal Fluids Alter the Features of Silver Nanoparticles. Small 16(21):e1907687. https:\/\/doi.org\/10.1002\/smll.201907687","journal-title":"Small"},{"issue":"7","key":"4846_CR171","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3390\/nano10071403","volume":"10","author":"B Begines","year":"2020","unstructured":"Begines B, Ortiz T, P\u00e9rez-Aranda M, Mart\u00ednez G, Merinero M, Arg\u00fcelles-Arias F et al (2020) Polymeric Nanoparticles for Drug Delivery, Recent Developments and Future Prospects. Nanomaterials (Basel) 10(7):1403. https:\/\/doi.org\/10.3390\/nano10071403","journal-title":"Nanomaterials (Basel)"},{"issue":"5","key":"4846_CR172","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/bjh.12446","volume":"162","author":"F Hagemeister","year":"2013","unstructured":"Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A et al (2013) Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(\u00ae)) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol 162(5):631\u2013638. https:\/\/doi.org\/10.1111\/bjh.12446","journal-title":"Br J Haematol"},{"issue":"4","key":"4846_CR173","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.7314\/apjcp.2013.14.4.2591","volume":"14","author":"X Xu","year":"2013","unstructured":"Xu X, Wang L, Xu HQ, Huang XE, Qian YD, Xiang J (2013) Clinical comparison between paclitaxel liposome (Lipusu\u00ae) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev 14(4):2591\u20132594. https:\/\/doi.org\/10.7314\/apjcp.2013.14.4.2591","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"4846_CR174","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/btm2.10003","volume":"1","author":"AC Anselmo","year":"2016","unstructured":"Anselmo AC, Mitragotri S (2016) Nanoparticles in the clinic. Bioeng Transl Med 1(1):10\u201329. https:\/\/doi.org\/10.1002\/btm2.10003","journal-title":"Bioeng Transl Med"},{"issue":"1","key":"4846_CR175","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nano.2012.05.013","volume":"9","author":"ML Etheridge","year":"2013","unstructured":"Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J (2013) The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 9(1):1\u201314. https:\/\/doi.org\/10.1016\/j.nano.2012.05.013","journal-title":"Nanomedicine"},{"issue":"12","key":"4846_CR176","first-page":"742","volume":"42","author":"CL Ventola","year":"2017","unstructured":"Ventola CL (2017) Progress in nanomedicine: approved and investigational nanodrugs. P T 42(12):742\u2013755","journal-title":"P T"},{"key":"4846_CR177","doi-asserted-by":"publisher","first-page":"102314","DOI":"10.1016\/j.nantod.2024.102314","volume":"56","author":"MM Mahmud","year":"2024","unstructured":"Mahmud MM, Pandey N, Winkles JA, Woodworth GF, Kim AJ (2024) Toward the scale-up production of polymeric nanotherapeutics for cancer clinical trials. Nano Today 56:102314. https:\/\/doi.org\/10.1016\/j.nantod.2024.102314","journal-title":"Nano Today"},{"issue":"37","key":"4846_CR178","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.2174\/0113816128354250250326045943","volume":"31","author":"MS Jain","year":"2025","unstructured":"Jain MS, Prasanthi S, Bommala ND, Goudanavar P, Naveen NR (2025) Harnessing the human microbiome for innovative drug delivery systems: exploring pharmacomicrobiomics and targeted therapies. Curr Pharm Des 31(37):2959\u20132971. https:\/\/doi.org\/10.2174\/0113816128354250250326045943","journal-title":"Curr Pharm Des"},{"issue":"6","key":"4846_CR179","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s42114-025-01492-x","volume":"8","author":"K Song","year":"2025","unstructured":"Song K, Ren L, Guo X, Ren G, Sun Y, Tian X et al (2025) Microbiota-responsive oral nano-amifostine enables colorectal-specific radioprotection and tumor immunity via gut microenvironment reprogramming. Adv Compos Hybrid Mater 8(6):432. https:\/\/doi.org\/10.1007\/s42114-025-01492-x","journal-title":"Adv Compos Hybrid Mater"},{"key":"4846_CR180","doi-asserted-by":"publisher","first-page":"122026","DOI":"10.1016\/j.biomaterials.2023.122026","volume":"295","author":"J Ma","year":"2023","unstructured":"Ma J, Dai L, Yu J, Cao H, Bao Y, Hu J et al (2023) Tumor microenvironment targeting system for glioma treatment via fusion cell membrane coating nanotechnology. Biomaterials 295:122026. https:\/\/doi.org\/10.1016\/j.biomaterials.2023.122026","journal-title":"Biomaterials"},{"issue":"19","key":"4846_CR181","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.1039\/d5bm00660k","volume":"13","author":"P Sultana","year":"2025","unstructured":"Sultana P, Kim YK, Cho SJ, Asadujjaman M, Jee JP (2025) Advances in cell membrane-coated nanoparticles: multifunctional platforms for targeted drug delivery, precision phototherapy, and enhanced immunotherapy. Biomater Sci 13(19):5232\u20135259. https:\/\/doi.org\/10.1039\/d5bm00660k","journal-title":"Biomater Sci"}],"container-title":["3 Biotech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13205-026-04846-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13205-026-04846-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13205-026-04846-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T18:59:19Z","timestamp":1782154759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13205-026-04846-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":181,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4846"],"URL":"https:\/\/doi.org\/10.1007\/s13205-026-04846-4","relation":{},"ISSN":["2190-572X","2190-5738"],"issn-type":[{"value":"2190-572X","type":"print"},{"value":"2190-5738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"It is not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"216"}}